ctDNA and MRD in Breast Cancer
Gain expert-driven insights and actionable recommendations on current and future applications of ctDNA and MRD testing in breast cancer.
FACULTY CO-CHAIR
Pat Whitworth, MD, FACS, FSSO
Targeted Medical Education Breast Care Network, Nashville, TN, USA
FACULTY CO-CHAIR
Peter Beitsch, MD
Targeted Medical Education Breast Care Network, Dallas, TX, USA
FACULTY MEMBERS
Monica Fornier, MD
Memorial Sloan Kettering Cancer Center
Adam Brufsky, MD, PhD
University of Pittsburgh School of Medicine
Barry Rosen, MD, FACS
Advocate Good Shepherd Hospital
Erica Giblin, MD, FACS, MBA
Ascension Medical Group St. Vincent
MinhTri Nguyen, MD
Stanford Health Care
Michael Alvarado, MD
UCSF Helen Diller Family Comprehensive Cancer Center
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Optimize ctDNA-Guided Strategies in Early Breast Cancer
- Advance MCED Screening Approaches
- Integrate ctDNA at Diagnosis and Pretreatment
- Leverage ctDNA During Neoadjuvant Therapy
- Refine Pre/Post-Surgery ctDNA Monitoring
- Personalize Adjuvant Therapy Using ctDNA
- Enhance Recurrence Surveillance With ctDNA
- Apply ctDNA Insights in Metastatic Breast Cancer
- Drive Consensus on ctDNA Clinical Utility
